升压药使用与动脉瘤性蛛网膜下腔出血合并Takotsubo心肌病结局的定量分析
本研究通过多机构病历回顾,纳入2015至2021年治疗的311例成人动脉瘤性蛛网膜下腔出血患者,其中13例(4.2%)诊断为Takotsubo心肌病。多数Takotsubo心肌病在出血后5天内诊断,且多发生在升压药启用之前;多因素分析显示升压药使用并非Takotsubo心肌病的预测因素。
要点
- 动脉瘤性蛛网膜下腔出血后Takotsubo心肌病多在出血后5天内诊断。
- 多数Takotsubo心肌病诊断早于升压药启动。
- 多因素分析未显示升压药使用与Takotsubo心肌病显著相关。
核心结论
- 在本组动脉瘤性蛛网膜下腔出血患者中,升压药使用在多因素分析中并非Takotsubo心肌病的预测因素,提示其使用可能不是相关因素,但仍需进一步研究。
研究设计与样本
- 多机构病历回顾,评估2015至2021年治疗的成人动脉瘤性蛛网膜下腔出血患者,以Takotsubo心肌病诊断为主要终点进行分组。
主要发现
- 共纳入311例患者,13例(4.2%)诊断为Takotsubo心肌病,中位诊断时间为出血后第4天(IQR 2-5)。
- 高级别破裂(Hunt Hess评分≥3)与Takotsubo心肌病相关(p=0.010)。
- 动脉瘤夹闭/栓塞后使用升压药与Takotsubo心肌病相关(p<0.001)。
- 单因素分析中,需多次血管内治疗的血管痉挛、心肌梗死、延长插管和总体不良结局在Takotsubo心肌病组更常见。
- 多因素分析中,升压药使用与Takotsubo心肌病无显著关联(OR 4.275,CI 0.295-61.952,p=0.287)。
临床怎么用
- 对于动脉瘤性蛛网膜下腔出血患者,Takotsubo心肌病多出现在出血后5天内,应在此窗口期关注心脏并发症。
- 在需要升压药治疗症状性血管痉挛时,现有数据未显示升压药使用会独立增加Takotsubo心肌病风险,但需个体化评估。
局限性
- 本研究为回顾性病历回顾,Takotsubo心肌病样本量小(13例),多因素分析置信区间宽,需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Takotsubo cardiomyopathy (TCM) is induced by catecholamine-induced cardiotoxicity. Though uncommon after aneurysmal subarachnoid hemorrhage (aSAH), TCM increases patient morbidity and mortality in an already-devastating disease process. The fear of worsening shock in TCM with blood pressure augmentation in patients with symptomatic vasospasm poses a dilemma for clinicians. This study aims to assess the relationship between vasopressor use after aSAH and TCM. METHOD: A multi-institutional chart review evaluated aSAH adult patients treated from 2015 to 2021. TCM diagnosis was the primary endpoint upon which the group was stratified. Baseline demographics, clinical presentation, aneurysm characteristics, adverse events, short-term outcomes, treatment variables, and vasopressor usage in average daily norepinephrine equivalent were collected. RESULTS: 311 patients were included; 13 (4.2%) had a TCM diagnosis. Median TCM diagnosis day was post-bleed day 4 (IQR 2-5). High-grade rupture (Hunt Hess score ≥ 3) was associated with TCM (p = 0.010). Vasopressor use after aneurysm securement was associated with TCM (p < 0.001). Vasospasm requiring multiple endovascular treatments, myocardial infarction, prolonged intubation, and general poor outcomes were significantly more prevalent in the TCM group on univariate analysis. On multivariate analysis, vasopressor use was not significantly associated with TCM (OR 4.275, CI 0.295-61.952, p = 0.287). CONCLUSION: In this sample of aSAH patients, a majority of TCM diagnoses were made within 5 days post-bleed. Most TCM patients were diagnosed prior to vasopressor initiation. Vasopressor use was not predictive of TCM in aSAH patients on multivariate analysis, suggesting its use is not a factor, though further study is needed.
引用
- Shah VS, Lacanienta P, Martinez O, et al. Pressor use and its impact on outcomes in aneurysmal subarachnoid hemorrhage patients with takotsubo cardiomyopathy: a quantitative analysis. Acta Neurochir (Wien). 2026. PMID: 41701379. doi:10.1007/s00701-026-06795-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。